TAK
Takeda Pharmaceutical Company Limited
Price Chart
Latest Quote
$20.27
-0.16 (-0.78%)
Current Price
| Previous Close | $20.43 |
| Open | $20.19 |
| Day High | $20.37 |
| Day Low | $20.19 |
| Volume | 2,147,165 |
Stock Information
Note: Financial values converted from JPY to USD
| Quarterly Dividend / Yield | $0.62 / 3.02% |
| Shares Outstanding | 3.19B |
| Quarterly Dividend Yield | 3.02% |
| Quarterly Dividend | $0.62 |
| Total Debt | $35.05B |
| Cash Equivalents | $2.92B |
| Revenue | $29.24B |
| Net Income | $-1.03B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $64.75B |
| EPS (TTM) | $-0.34 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.14T |
| Sales | $29.24B |
| Income | $-1.03B |
| Book/sh | $15.12 |
| Cash/sh | $144.35 |
| Employees | 47K |
Financial Ratios
| Quick Ratio | 0.51 |
| Current Ratio | 1.14 |
| Debt/Eq | 73.25 |
| EPS Growth TTM | -8.90% |
Returns & Margins
| ROA | 2.69% |
| ROE | -2.26% |
| Gross Margin | 64.47% |
| Operating Margin | 16.45% |
| Profit Margin | -3.54% |
Ownership
| Insider Ownership | 0.08% |
| Institutional Ownership | 3.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 38.25 |
| PEG | 0.46 |
| P/S | 0.01 |
| P/B | 1.34 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $22.62 |
Technical Indicators
| SMA20 | $19.08 |
| SMA50 | $18.71 |
| SMA200 | $17.49 |
| RSI | 78.79 |
| ATR | 0.3543 |
| Shares Float | 3.16B |
| Short Float | 0.09% |
| Short Ratio | 1.28 |
| Volatility | 0.10 |
| Rel Volume | 0.77 |
Performance History
| Week | +0.95% |
| Month | +7.25% |
| Quarter | +14.20% |
| 6 Months | +23.52% |
| YTD | +29.77% |
| Year | +44.68% |
| 3 Years | +49.02% |
| 5 Years | +53.56% |
| 10 Years | -5.90% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $20.27 | 2,147,165 |
| 2026-10-26 | $20.43 | 2,367,400 |
| 2026-10-23 | $20.24 | 2,099,200 |
| 2026-10-22 | $20.36 | 3,461,900 |
| 2026-10-21 | $19.93 | 1,671,400 |
| 2026-10-20 | $20.08 | 2,907,300 |
| 2026-10-19 | $19.61 | 2,877,500 |
| 2026-10-16 | $19.67 | 2,827,700 |
| 2026-10-15 | $19.45 | 4,387,200 |
| 2026-10-14 | $19.01 | 4,676,400 |
| 2026-10-13 | $18.52 | 2,925,000 |
| 2026-10-12 | $18.68 | 1,909,000 |
| 2026-10-09 | $18.73 | 2,043,100 |
| 2026-10-08 | $18.52 | 3,510,600 |
| 2026-10-07 | $18.37 | 2,556,500 |
| 2026-10-06 | $18.10 | 3,097,400 |
| 2026-10-05 | $17.81 | 3,404,600 |
| 2026-10-02 | $17.86 | 2,132,800 |
| 2026-10-01 | $17.86 | 2,402,900 |
| 2026-09-30 | $18.19 | 2,102,800 |
| 2026-09-29 | $18.51 | 2,415,100 |
| 2026-09-28 | $18.90 | 2,063,000 |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
đ° Latest News
No news articles available at the moment. Check back later for updates on TAK.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $9,463,352,523 | $9,323,373,176 | $8,613,872,827 | $7,155,615,929 |
| Cost Of Revenue | $10,021,860,617 | $10,076,886,893 | $9,097,783,937 | $7,933,323,608 |
| Total Revenue | $28,732,529,022 | $29,216,095,779 | $27,189,586,882 | $25,682,827,277 |
| Operating Revenue | $28,732,529,022 | $29,216,095,779 | $27,189,586,882 | $25,682,827,277 |
| Expenses | ||||
| Interest Expense | $944,565,662 | $875,618,612 | $762,262,825 | $745,925,206 |
| Total Expenses | $25,770,771,115 | $26,242,100,600 | $25,213,378,979 | $21,934,408,523 |
| Other Income Expense | $-2,952,709,085 | $-833,652,229 | $-743,833,582 | $-569,686,801 |
| Net Non Operating Interest Income Expense | $-916,832,521 | $-1,023,836,915 | $-895,718,603 | $-786,813,893 |
| Total Other Finance Cost | $79,896,189 | $273,447,879 | $205,470,117 | $76,012,656 |
| Interest Expense Non Operating | $944,565,662 | $875,618,612 | $762,262,825 | $745,925,206 |
| Operating Expense | $15,748,910,498 | $16,165,213,706 | $16,115,595,042 | $14,001,084,916 |
| Other Operating Expenses | $484,631,699 | $361,812,592 | $582,357,703 | $143,588,673 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-971,775,898 | $688,246,139 | $918,700,953 | $2,021,585,929 |
| Interest Income | $107,629,330 | $125,229,576 | $72,014,340 | $35,123,969 |
| Normalized Income | $791,520,046 | $1,187,462,737 | $1,470,320,125 | $2,577,409,315 |
| Net Income From Continuing And Discontinued Operation | $-971,775,898 | $688,246,139 | $918,700,953 | $2,021,585,929 |
| Total Operating Income As Reported | $39,645,192 | $2,184,636,903 | $1,365,135,017 | $3,127,901,678 |
| Net Income Common Stockholders | $-971,775,898 | $688,246,139 | $918,700,953 | $2,021,585,929 |
| Net Income | $-971,775,898 | $688,246,139 | $918,700,953 | $2,021,585,929 |
| Net Income Including Noncontrolling Interests | $-970,086,019 | $689,617,172 | $919,529,950 | $2,021,719,844 |
| Net Income Continuous Operations | $-970,086,019 | $689,617,172 | $919,529,950 | $2,021,719,844 |
| Pretax Income | $-907,783,699 | $1,116,493,282 | $336,642,965 | $2,391,911,684 |
| Special Income Charges | $-2,977,948,858 | $-856,717,478 | $-726,871,026 | $-698,665,994 |
| Earnings From Equity Interest | $-13,882,513 | $-25,418,326 | $41,277,678 | $87,911,953 |
| Interest Income Non Operating | $107,629,330 | $125,229,576 | $72,014,340 | $35,123,969 |
| Operating Income | $2,961,757,907 | $2,973,995,179 | $1,976,207,904 | $3,748,418,754 |
| Depreciation Amortization Depletion Income Statement | $4,040,047,177 | $4,101,832,968 | $4,158,485,354 | $3,459,105,146 |
| Depreciation And Amortization In Income Statement | $4,040,047,177 | $4,101,832,968 | $4,158,485,354 | $3,459,105,146 |
| Amortization Of Intangibles Income Statement | $4,040,047,177 | $4,101,832,968 | $4,158,485,354 | $3,459,105,146 |
| Gross Profit | $18,710,668,405 | $19,139,208,886 | $18,091,802,946 | $17,749,503,670 |
| Net Interest Income | - | $-1,023,836,915 | - | $-786,813,893 |
| Per Share | ||||
| Diluted EPS | $0.38 | $0.21 | $0.29 | $0.64 |
| Basic EPS | $0.39 | $0.22 | $0.29 | $0.65 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,175,530,629 | $-309,017,304 | $-233,492,089 | $-101,775,368 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $7,574,163,806 | $7,655,692,482 | $6,526,413,514 | $8,032,248,468 |
| Total Unusual Items | $-2,938,826,572 | $-808,233,902 | $-785,111,260 | $-657,598,754 |
| Total Unusual Items Excluding Goodwill | $-2,938,826,572 | $-808,233,902 | $-785,111,260 | $-657,598,754 |
| Reconciled Depreciation | $4,598,555,271 | $4,855,346,685 | $4,642,396,463 | $4,236,812,825 |
| EBITDA (Bullshit earnings) | $4,635,337,234 | $6,847,458,580 | $5,741,302,253 | $7,374,649,714 |
| EBIT | $36,781,963 | $1,992,111,894 | $1,098,905,790 | $3,137,836,889 |
| Diluted Average Shares | $20,441,576 | $20,473,971 | $20,155,381 | $20,021,836 |
| Basic Average Shares | $20,088,028 | $20,136,633 | $19,952,685 | $19,791,464 |
| Diluted NI Availto Com Stockholders | $-971,775,898 | $688,246,139 | $918,700,953 | $2,021,585,929 |
| Minority Interests | $-1,683,502 | $-1,371,034 | $-828,997 | $-133,915 |
| Tax Provision | $62,302,320 | $426,876,110 | $-582,886,985 | $370,191,839 |
| Gain On Sale Of Ppe | $1,052,189 | $2,314,815 | $918,274 | $13,353,230 |
| Gain On Sale Of Business | $116,474,091 | $65,031,633 | $49,937,509 | $43,407,563 |
| Other Special Charges | $2,628,768,906 | $67,371,956 | $115,804,517 | $156,929,149 |
| Write Off | $8,691,716 | $43,439,448 | $10,745,078 | $195,318,092 |
| Restructuring And Mergern Acquisition | $458,014,516 | $813,252,523 | $651,177,215 | $403,179,547 |
| Gain On Sale Of Security | $39,122,286 | $48,483,576 | $-58,240,234 | $41,067,241 |
| Amortization | $4,040,047,177 | $4,101,832,968 | $4,158,485,354 | $3,459,105,146 |
| Research And Development | $4,310,300,229 | $4,656,585,067 | $4,654,652,867 | $4,038,650,636 |
| Selling General And Administration | $6,913,931,392 | $7,044,983,079 | $6,720,099,119 | $6,359,740,460 |
Fetched: 2026-10-22
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-11,471,515,077 | $-12,887,116,886 | $-15,377,806,761 | $-17,257,538,535 |
| Total Assets | $98,915,333,469 | $90,860,274,827 | $96,347,266,281 | $89,007,185,745 |
| Total Non Current Assets | $79,207,509,102 | $74,782,883,798 | $80,031,468,442 | $73,715,658,450 |
| Other Non Current Assets | $491,085,123 | $448,181,335 | $326,586,592 | $403,817,237 |
| Non Current Deferred Assets | $3,483,445,776 | $2,364,204,050 | $2,511,637,994 | $2,333,964,787 |
| Non Current Deferred Taxes Assets | $3,483,445,776 | $2,364,204,050 | $2,511,637,994 | $2,333,964,787 |
| Investmentin Financial Assets | $2,805,460,071 | $2,239,082,881 | $2,173,101,090 | $1,783,510,718 |
| Goodwill And Other Intangible Assets | $58,848,322,590 | $57,111,458,900 | $61,758,689,054 | $57,777,143,564 |
| Other Intangible Assets | $21,804,842,655 | $23,158,097,506 | $27,259,229,015 | $27,227,178,712 |
| Current Assets | $19,707,830,744 | $16,077,391,030 | $16,315,810,593 | $15,291,527,295 |
| Other Current Assets | $1,037,126,376 | $1,017,772,482 | $1,076,899,106 | $1,025,826,508 |
| Assets Held For Sale Current | $114,497,252 | $85,431,339 | $59,541,122 | $97,152,082 |
| Inventory | $8,906,107,056 | $7,762,913,690 | $7,715,214,473 | $6,290,538,334 |
| Receivables | $5,588,384,175 | $4,624,872,740 | $4,448,589,697 | $4,347,094,946 |
| Receivables Adjustments Allowances | $-1,079,800,596 | $-761,918,473 | $-677,456,423 | $-632,971,163 |
| Other Receivables | $231,398,596 | $370,179,086 | $356,876,871 | $471,884,275 |
| Taxes Receivable | $204,290,391 | $100,684,885 | $186,250,139 | $205,744,324 |
| Accounts Receivable | $6,232,495,784 | $4,915,927,242 | $4,582,919,111 | $4,302,437,510 |
| Cash Cash Equivalents And Short Term Investments | $4,061,715,886 | $2,586,400,778 | $3,015,566,195 | $3,530,915,425 |
| Cash And Cash Equivalents | $3,794,600,269 | $2,455,827,359 | $2,919,345,140 | $3,402,267,830 |
| Cash Equivalents | $2,871,480,124 | $965,277,836 | $1,610,875,263 | $1,938,405,636 |
| Cash Financial | $923,120,145 | $1,490,549,523 | $1,308,476,255 | $1,463,862,194 |
| Debt | ||||
| Net Debt | $27,336,395,890 | $26,337,569,180 | $27,968,780,379 | $24,543,485,560 |
| Total Debt | $31,130,996,159 | $28,793,396,539 | $30,888,125,519 | $27,945,753,391 |
| Long Term Debt And Capital Lease Obligation | $27,865,021,828 | $25,292,867,046 | $28,546,202,360 | $25,780,157,913 |
| Long Term Debt | $27,865,021,828 | $25,292,867,046 | $28,546,202,360 | $25,780,157,913 |
| Current Debt And Capital Lease Obligation | $3,265,974,332 | $3,500,529,493 | $2,341,923,159 | $2,165,595,478 |
| Current Debt | $3,265,974,332 | $3,500,529,493 | $2,341,923,159 | $2,165,595,478 |
| Other Current Borrowings | $3,265,974,332 | $3,500,529,493 | $2,341,923,159 | $2,165,595,478 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $51,530,822,660 | $46,630,225,487 | $49,961,658,705 | $48,484,079,797 |
| Total Non Current Liabilities Net Minority Interest | $33,470,967,987 | $30,646,389,968 | $35,211,230,565 | $32,656,994,874 |
| Other Non Current Liabilities | $4,279,314,868 | $4,041,418,211 | $4,902,369,951 | $3,823,953,143 |
| Non Current Deferred Liabilities | $170,926,446 | $224,167,190 | $725,544,631 | $1,725,716,867 |
| Non Current Deferred Taxes Liabilities | $170,926,446 | $224,167,190 | $725,544,631 | $1,725,716,867 |
| Current Liabilities | $18,059,854,673 | $15,983,835,519 | $14,750,428,140 | $15,827,084,923 |
| Other Current Liabilities | $4,669,109,300 | $5,199,750,338 | $4,871,984,019 | $4,797,788,780 |
| Payables And Accrued Expenses | $3,757,429,315 | $3,883,774,849 | $4,192,346,696 | $5,621,939,426 |
| Payables | $3,757,429,315 | $3,883,774,849 | $4,192,346,696 | $5,621,939,426 |
| Other Payable | $1,064,795,748 | $1,065,522,715 | $1,451,165,785 | $2,179,497,121 |
| Total Tax Payable | $624,171,041 | $851,297,113 | $700,859,648 | $1,481,845,054 |
| Income Tax Payable | $624,171,041 | $851,297,113 | $700,859,648 | $1,481,845,054 |
| Accounts Payable | $2,068,462,526 | $1,966,955,021 | $2,040,321,263 | $1,960,597,251 |
| Tradeand Other Payables Non Current | - | $2,021,478 | $27,937,202 | $156,603,927 |
| Equity | ||||
| Common Stock Equity | $47,376,807,514 | $44,224,342,014 | $46,380,882,293 | $40,519,605,030 |
| Total Equity Gross Minority Interest | $47,384,510,810 | $44,230,049,340 | $46,385,607,576 | $40,523,105,948 |
| Stockholders Equity | $47,376,807,514 | $44,224,342,014 | $46,380,882,293 | $40,519,605,030 |
| Other Equity Interest | $21,027,237,006 | $14,997,928,410 | $16,001,620,696 | $9,617,118,730 |
| Gains Losses Not Affecting Retained Earnings | $-18,161,413 | $0 | - | - |
| Other Equity Adjustments | $-18,161,413 | - | - | - |
| Retained Earnings | $4,542,782,898 | $7,573,117,995 | $8,871,563,385 | $9,827,735,006 |
| Long Term Equity Investment | $56,091,219 | $68,883,281 | $572,843,367 | $632,422,750 |
| Other | ||||
| Treasury Shares Number | $72,647 | $110,320 | $85,484 | $177,069 |
| Ordinary Shares Number | $10,074,463 | $10,035,008 | $10,005,443 | $9,913,076 |
| Share Issued | $10,147,110 | $10,145,328 | $10,090,927 | $10,090,145 |
| Tangible Book Value | $-11,471,515,077 | $-12,887,116,886 | $-15,377,806,761 | $-17,257,538,535 |
| Invested Capital | $78,507,803,673 | $73,017,738,553 | $77,269,007,812 | $68,465,358,420 |
| Working Capital | $1,647,976,071 | $93,555,510 | $1,565,382,453 | $-535,557,628 |
| Total Capitalization | $75,241,829,341 | $69,517,209,060 | $74,927,084,653 | $66,299,762,943 |
| Minority Interest | $7,703,296 | $5,707,326 | $4,725,283 | $3,500,918 |
| Treasury Stock | $313,284,378 | $477,087,826 | $326,873,553 | $639,711,548 |
| Additional Paid In Capital | $11,327,620,312 | $11,323,545,473 | $11,143,085,560 | $11,024,577,237 |
| Capital Stock | $10,810,613,088 | $10,806,837,963 | $10,691,486,206 | $10,689,885,604 |
| Common Stock | $10,810,613,088 | $10,806,837,963 | $10,691,486,206 | $10,689,885,604 |
| Employee Benefits | $916,252,223 | $863,617,285 | $917,521,227 | $813,654,268 |
| Non Current Pension And Other Postretirement Benefit Plans | $916,252,223 | $863,617,285 | $917,521,227 | $813,654,268 |
| Long Term Provisions | $239,452,621 | $224,320,236 | $91,655,194 | $356,908,755 |
| Current Provisions | $6,367,341,726 | $3,399,780,839 | $3,344,174,265 | $3,241,761,240 |
| Investments And Advances | $2,861,551,289 | $2,307,966,163 | $2,745,944,457 | $2,415,933,468 |
| Available For Sale Securities | $2,805,460,071 | $2,239,082,881 | $2,173,101,090 | $1,783,510,718 |
| Goodwill | $37,043,479,935 | $33,953,361,394 | $34,499,460,039 | $30,549,964,852 |
| Net PPE | $13,523,104,324 | $12,551,073,350 | $12,688,610,344 | $10,784,799,394 |
| Accumulated Depreciation | $-9,768,582,875 | $-8,322,046,721 | $-7,784,289,061 | $-6,426,347,188 |
| Gross PPE | $23,291,687,199 | $20,873,120,070 | $20,472,899,406 | $17,211,146,582 |
| Construction In Progress | $2,518,167,941 | $2,051,168,372 | $1,777,172,079 | $1,322,569,205 |
| Machinery Furniture Equipment | $8,371,429,440 | $7,495,185,891 | $7,313,597,267 | $6,333,850,243 |
| Buildings And Improvements | $11,708,455,199 | $10,661,387,235 | $10,707,160,628 | $8,928,349,685 |
| Land And Improvements | $693,640,997 | $665,378,573 | $674,963,055 | $626,383,825 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,722,509,347 | $2,063,010,276 | $2,229,300,716 | $1,715,654,118 |
| Work In Process | $4,087,606,103 | $3,521,324,567 | $3,332,995,558 | $2,783,568,171 |
| Raw Materials | $2,095,991,607 | $2,178,578,848 | $2,152,918,199 | $1,791,322,422 |
| Other Short Term Investments | $267,115,617 | $130,573,419 | $96,221,055 | $128,647,595 |
| Other Inventories | - | - | - | $-6,377 |
Fetched: 2026-10-22
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,996,862,806 | $4,320,713,708 | $1,502,487,082 | $2,190,254,953 |
| Operating Activities | ||||
| Operating Cash Flow | $6,641,102,073 | $6,741,544,636 | $4,568,054,555 | $6,231,226,780 |
| Cash Flow From Continuing Operating Activities | $6,641,108,450 | $6,741,538,259 | $4,568,054,555 | $6,231,233,157 |
| Operating Gains Losses | $744,228,950 | $26,961,536 | $-349,613,581 | $11,688,859 |
| Investing Activities | ||||
| Capital Expenditure | $-2,644,239,267 | $-2,420,830,928 | $-3,065,567,474 | $-4,040,971,828 |
| Investing Cash Flow | $-2,353,975,501 | $-2,340,705,171 | $-2,958,001,913 | $-3,871,429,169 |
| Cash Flow From Continuing Investing Activities | $-2,353,975,501 | $-2,340,711,548 | $-2,957,995,536 | $-3,871,429,169 |
| Net Other Investing Changes | $-17,695,899 | $-7,078,360 | $-25,533,110 | $-19,462,301 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-329,067,207 | $-330,706,070 | $-14,832,671 | $-171,723,559 |
| Financing Cash Flow | $-3,168,171,806 | $-4,791,762,608 | $-2,260,075,638 | $-4,522,166,378 |
| Cash Flow From Continuing Financing Activities | $-3,168,165,429 | $-4,791,749,855 | $-2,260,069,262 | $-4,522,172,755 |
| Net Other Financing Charges | $-82,976,232 | $192,780,085 | $216,559,548 | $-58,520,818 |
| Cash Dividends Paid | $-1,988,961,705 | $-1,928,999,708 | $-1,831,369,358 | $-1,781,808,086 |
| Net Common Stock Issuance | $-329,067,207 | $-330,706,070 | $-14,832,671 | $-171,723,559 |
| Dividends Received Cfi | $8,277,217 | $4,049,332 | $84,117,697 | $22,714,520 |
| Common Stock Dividend Paid | - | - | - | $-1,781,808,086 |
| Other | ||||
| Repayment Of Debt | $-3,730,384,879 | $-8,712,529,858 | $-2,394,443,313 | $-2,551,213,040 |
| Issuance Of Debt | $3,737,246,424 | $6,708,180,691 | $2,404,091,564 | $733,343,580 |
| End Cash Position | $3,794,600,269 | $2,455,827,359 | $2,919,345,140 | $3,402,267,830 |
| Beginning Cash Position | $2,455,827,359 | $2,919,345,140 | $3,402,267,830 | $5,418,420,640 |
| Effect Of Exchange Rate Changes | $219,824,521 | $-72,601,014 | $167,100,306 | $146,215,956 |
| Changes In Cash | $1,118,948,389 | $-390,916,767 | $-650,022,996 | $-2,162,368,766 |
| Interest Paid Cff | $-774,028,207 | $-720,487,749 | $-640,081,408 | $-692,244,455 |
| Common Stock Payments | $-329,067,207 | $-330,706,070 | $-14,832,671 | $-171,723,559 |
| Net Issuance Payments Of Debt | $6,861,545 | $-2,004,349,167 | $9,648,251 | $-1,817,869,459 |
| Net Short Term Debt Issuance | $-2,179,497,121 | $175,301,000 | $1,766,401,494 | $255,076,028 |
| Short Term Debt Payments | $-2,179,497,121 | - | - | - |
| Net Long Term Debt Issuance | $2,186,358,666 | $-2,179,650,167 | $-1,756,753,243 | $-2,072,945,487 |
| Long Term Debt Payments | $-1,550,887,758 | $-8,712,529,858 | $-2,394,443,313 | $-2,551,213,040 |
| Long Term Debt Issuance | $3,737,246,424 | $6,532,879,691 | $637,690,070 | $478,267,552 |
| Interest Received Cfi | $110,696,619 | $112,616,066 | $71,172,589 | $32,228,856 |
| Net Investment Purchase And Sale | $-66,319,767 | $-522,529,620 | $-204,347,783 | $77,179,629 |
| Sale Of Investment | $44,835,989 | $187,748,710 | $51,149,121 | $141,911,548 |
| Purchase Of Investment | $-111,155,756 | $-710,278,331 | $-255,496,903 | $-64,731,919 |
| Net Business Purchase And Sale | $214,149,079 | $492,570,941 | $127,276,561 | $50,747,376 |
| Sale Of Business | $218,121,888 | $498,973,349 | $127,276,561 | $50,747,376 |
| Purchase Of Business | $-3,972,809 | $-6,402,408 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-1,521,885,613 | $-1,140,381,152 | $-1,946,931,553 | $-3,144,016,106 |
| Purchase Of Intangibles | $-1,521,885,613 | $-1,140,381,152 | $-1,946,931,553 | $-3,144,016,106 |
| Net PPE Purchase And Sale | $-1,081,197,137 | $-1,279,952,378 | $-1,063,756,313 | $-890,821,143 |
| Sale Of PPE | $41,156,517 | $497,398 | $54,879,607 | $6,134,578 |
| Purchase Of PPE | $-1,122,353,654 | $-1,280,449,776 | $-1,118,635,921 | $-896,955,722 |
| Taxes Refund Paid | $-1,100,410,739 | $-959,168,765 | $-1,288,382,641 | $-1,185,886,716 |
| Change In Working Capital | $1,274,774,334 | $-378,609,348 | $-1,632,505,710 | $-161,106,019 |
| Change In Other Working Capital | $2,653,555,919 | $288,019,097 | $-809,235,076 | $203,416,755 |
| Change In Other Current Liabilities | $-520,393,359 | $-22,242,630 | $-118,406,292 | $201,950,068 |
| Change In Payables And Accrued Expense | $-20,087,237 | $-45,390,779 | $-63,099,432 | $-540,786,687 |
| Change In Payable | $-20,087,237 | $-45,390,779 | $-63,099,432 | $-540,786,687 |
| Change In Inventory | $-390,859,375 | $-223,019,348 | $-738,081,618 | $-504,763,575 |
| Change In Receivables | $-447,441,615 | $-375,975,688 | $96,316,708 | $479,077,419 |
| Other Non Cash Items | $632,027,382 | $940,369,662 | $1,318,570,888 | $114,822,474 |
| Stock Based Compensation | $464,078,948 | $464,665,623 | $451,937,330 | $386,899,319 |
| Unrealized Gain Loss On Investment Securities | $6,415,162 | $-3,838,894 | $132,365,328 | $25,450,211 |
| Asset Impairment Charge | $929,216,462 | $679,324,855 | $956,643,512 | $410,634,144 |
| Deferred Tax | $62,302,320 | $426,876,110 | $-582,886,985 | $370,191,839 |
| Deferred Income Tax | $62,302,320 | $426,876,110 | $-582,886,985 | $370,191,839 |
| Depreciation Amortization Depletion | $4,598,555,271 | $4,855,346,685 | $4,642,396,463 | $4,236,812,825 |
| Depreciation And Amortization | $4,598,555,271 | $4,855,346,685 | $4,642,396,463 | $4,236,812,825 |
| Earnings Losses From Equity Investments | $13,882,513 | $25,418,326 | $-41,277,678 | $55,032,653 |
| Gain Loss On Investment Securities | $827,256,197 | $37,910,675 | $-296,985,019 | - |
| Gain Loss On Sale Of PPE | $19,564,331 | $28,664,169 | $38,593,003 | $63,769 |
| Gain Loss On Sale Of Business | $-116,474,091 | $-65,031,633 | $-49,943,886 | $-43,407,563 |
| Net Income From Continuing Operations | $-970,086,019 | $689,617,172 | $919,529,950 | $2,021,719,844 |
| Short Term Debt Issuance | - | $175,301,000 | $1,766,401,494 | $255,076,028 |
Fetched: 2026-10-22